Rhythm Pharmaceuticals, Inc. research snapshot
RYTM AI stock analysis currently reads Rhythm Pharmaceuticals as a commercial-stage rare-obesity company with a growing IMCIVREE revenue base and a wider MC4R agonist pipeline. RYTM closed at $108.40 on July 10, 2026, implying a calculated market value of about $7.43 billion using the latest SEC share count. Q1 2026 product revenue reached $60.1 million, up 59% year over year, but the company still reported a $55.6 million quarterly net loss and used $44.2 million in operating cash. The central RYTM AI stock forecast question is whether acquired hypothalamic obesity expansion and future pipeline assets can turn revenue growth into durable earnings before commercial spending, clinical risk, and dilution weigh on per-share value. This is informational research, not investment advice.
Current price
$108.40 close on July 10, 2026
Market cap
$7.43 billion calculated from $108.40 x 68.532607 million shares; StockAnalysis reported $7.76 billion on July 8, a 4.27% date and share-count variance
AI score
56 / 100
Rating
Commercial rare-obesity platform with real product revenue and meaningful expansion catalysts, but negative earnings, customer concentration, and clinical execution risk
Trend status
Above the 50-day and 200-day averages, but the July 10 pullback weakened short-term momentum
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Rhythm sells IMCIVREE for rare MC4R pathway diseases and is expanding into acquired hypothalamic obesity. Product revenue is real and growing, but the company remains dependent on one commercial product and a still-developing pipeline. | High |
| Moat | The moat is based on MC4R biology, clinical evidence, regulatory approvals, orphan-disease expertise, patient identification, and intellectual property. Switching costs and network effects are limited, so reimbursement and competing therapies remain important. | Medium |
| Management | David Meeker and the team have moved Rhythm from development into broader commercial execution while keeping a pipeline of next-generation MC4R agonists. The capital allocation test is whether higher selling and clinical spending produces durable revenue and per-share value. | Medium |
| Financial trend | FY2025 total revenue was $189.76 million, up 45.83%, while net loss was $196.54 million and free cash flow was negative $116.63 million. Q1 2026 product revenue rose 59% year over year to $60.11 million, but net loss was $55.64 million and operating cash use was $44.19 million. | High |
| Valuation | At $108.40, the exact valuation check produced negative TTM P/E of 34.63x, about 60.22x book value, and negative P/FCF of 59.89x. These ratios are not conventional value signals because earnings and free cash flow remain negative. | High |
| Technical trend | The July 9 technical snapshot put price above the 50-day average of $93.99 and 200-day average of $98.41, with RSI 75.08 and beta 1.88. The July 10 close fell 6.13% from July 9, so momentum is strong over the longer window but vulnerable to a fast reset. | Medium |
| Risk level | Risk is high. Commercial adoption, reimbursement, single-product concentration, clinical readouts, manufacturing, preferred stock, royalty obligations, and equity issuance can all change the thesis. | High |
| AI confidence | The reported financial and regulatory facts are well supported. Confidence is lower for future revenue conversion, pipeline probability, normalized margins, and price scenarios. | Medium |
| Investment certainty | Investment certainty is lower than AI confidence. A good product and growing revenue do not yet prove that Rhythm can fund its commercial and clinical plans without continued losses or dilution. | Low-medium |
RYTM AI stock forecast
The RYTM AI stock forecast is a scenario range, not a point target. StockAnalysis listed a 16-analyst average price reference of $139.73, but analyst targets are not company guidance and can change quickly. The required financial_rigor.py three-scenario calculation used negative TTM EPS of $3.13 in absolute loss terms and produced mechanically negative reference values of negative $269.50, negative $119.00, and negative $34.20 after three years. Because that model is not decision-useful for a loss-making biotech, the practical ranges below focus on product growth, pipeline execution, cash burn, and market multiple risk.
$140 to $180 scenario range
More likely if IMCIVREE uptake in acquired hypothalamic obesity scales in the United States and Europe, Japan approves the pending application, PWS data supports a credible Phase 3 path, and bivamelagon or RM-718 adds value without excessive dilution.
$90 to $140 scenario range
More likely if product revenue continues to grow but market access, specialty pharmacy timing, marketing expense, clinical spending, and the negative earnings profile keep the market focused on execution rather than near-term profits.
$55 to $90 scenario range
More likely if acquired hypothalamic obesity adoption is slow, reimbursement is difficult, EMANATE setbacks reduce confidence in the broader platform, pipeline studies disappoint, cash burn accelerates, or Rhythm raises equity while valuation is under pressure.
RYTM AI technical analysis
RYTM AI technical analysis uses the July 10, 2026 close and the latest StockAnalysis technical snapshot checked July 9. Price remained above the 50-day average near $93.99 and the 200-day average near $98.41, but the July 10 close dropped from $115.48 to $108.40. RSI 75.08 before that session indicated extended momentum, not a reliable reversal signal. These are reference levels, not trading instructions.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $108.40 | Official Rhythm stock information shows the July 10 close, a high of $114.95, a low of $108.22, and volume of 506,150 shares. |
| Immediate support reference | $106.40 to $108.22 | The July 10 low and the June 26 low from the historical price record define the nearest price-action zone. A break below it would show continued short-term weakness, not a confirmed floor. |
| Intermediate support reference | $98.41 to $100.00 | The July 9 technical snapshot placed the 200-day average near $98.41. The round $100 level is a market reference, not a guarantee of support. |
| Near resistance reference | $114.95 to $115.92 | The July 10 high and July 9 high define the nearest recovery zone. A sustained break above it would need volume and commercial or clinical confirmation. |
| Moving averages | 50-day $93.99; 200-day $98.41 | StockAnalysis technical statistics checked July 9, 2026. The averages can change after each trading session and should be refreshed before use. |
| Momentum | RSI 75.08 before the July 10 pullback | The snapshot described strong and extended momentum. The July 10 decline means the indicator should be recalculated from current data before any decision. |
| Volume and volatility | 506,150 shares on July 10; 20-day average about 1.11 million; beta 1.88 | The official stock record supplies the session volume and StockAnalysis supplies the 20-day average and beta. Clinical and regulatory news can create gaps larger than ordinary daily volatility. |
| Invalidation reference | Sustained close below $98.41 | A sustained close below the 200-day average would weaken the longer-term chart structure. A clinical or regulatory announcement can invalidate technical levels immediately. |
RYTM AI trading strategy
The RYTM AI trading strategy is a rules-based research framework, not personalized advice. Use a live chart, an FDA and clinical-trial calendar, current filings, position sizing, and a plan for overnight gaps because biotech and commercial catalysts can overwhelm ordinary stops.
Wait for price to reclaim and hold the $114.95 to $115.92 resistance reference with volume, then confirm that product launch data, reimbursement progress, or a pipeline update supports the move. A breakout without a fundamental catalyst is only a price signal.
A failed breakout followed by a close below $108.22 weakens the short-term setup. A sustained close below $98.41 is a broader trend warning.
If price holds the $106.40 to $108.22 zone, monitor product revenue, patient start forms, payer access, cash, and share count. The setup tests whether the pullback is technical rather than a change in commercial or clinical probability.
Do not average down only because price reaches a historical level. Reassess after a reimbursement setback, trial failure, safety signal, financing, or a material change in product demand.
Track Japan PMDA review, acquired hypothalamic obesity launch metrics, IMCIVREE revenue and gross margin, PWS Phase 3 planning, RM-718 data, bivamelagon Phase 3 plans, cash runway, royalty obligations, and common share count.
Lower confidence if revenue growth depends on a small number of customers, operating expenses outrun product revenue, clinical timelines slip, or new equity is issued at an unfavorable price.
Investment research summary
Rhythm sells IMCIVREE, a precision medicine built around MC4R agonism, for rare genetic obesity disorders and acquired hypothalamic obesity. Customers pay for an approved treatment that addresses severe hyperphagia and obesity caused by impaired MC4R pathway signaling. Product revenue reached $194.77 million in 2025 and $60.11 million in Q1 2026, but the company is still building the commercial organization needed to convert approval into durable operating leverage. The key question is whether rare-disease market access can expand faster than sales, marketing, and clinical costs. Buffett-style question: would this remain a good business if the pipeline stopped expanding?
Rhythm has a developing moat from MC4R pathway expertise, clinical data, regulatory approvals, orphan-disease infrastructure, physician education, patient identification, and intellectual property. The approval and NEJM publication of TRANSCEND results strengthen evidence for acquired hypothalamic obesity, while the positive preliminary PWS data creates a possible next market. There are limited network effects and patients can be sensitive to reimbursement and treatment alternatives. Buffett-style question: which part of the moat would still exist ten years after a better-funded competitor entered?
The failure paths are concentrated. IMCIVREE may grow more slowly than expected in acquired hypothalamic obesity, payers may restrict access, the EMANATE miss may signal limits to broader genetic indications, or future PWS, RM-718, and bivamelagon studies may fail. Even successful revenue growth may not create per-share value if selling costs, royalty obligations, preferred stock, or equity issuance consume the economics. Munger-style question: what fact would make the current valuation look obviously too optimistic?
David Meeker is Chairman, President, and CEO. Management has invested heavily in commercialization, expanded international infrastructure, and continued clinical work while using equity and preferred financing to extend the runway. The 2025 follow-on offering issued 2.367647 million common shares, and a February 2026 ATM agreement permits up to $200 million of additional sales. The company reported cash, cash equivalents, and short-term investments of $340.6 million at March 31, 2026 and said that resources should fund planned operations for at least 24 months. The capital allocation test is whether these investments create profitable product revenue before dilution becomes a larger part of the return. Management question: if the CEO left, would the commercial and clinical system still compound?
Rare obesity medicine sits inside a long-term shift toward genetically defined, mechanism-specific treatment rather than one broad obesity category. MC4R agonism addresses a narrower population than mainstream GLP-1 markets, but severe hyperphagia and hypothalamic obesity have limited treatment options. Rhythm is positioned at the approved-product and specialist-care layer, with the opportunity to expand through Europe, Japan, PWS, acquired hypothalamic obesity, and next-generation agents. The ceiling is constrained by rare-disease prevalence, payer budgets, manufacturing, and competitors. Li Lu-style question: in twenty years, will MC4R agonism be a durable rare-disease standard or a short-lived niche?
At $108.40, the calculated equity value is about $7.43 billion against negative TTM earnings and negative free cash flow. The exact check produced negative TTM P/E of 34.63x, about 60.22x book value, and negative P/FCF of 59.89x. The price therefore depends on future product growth, acquired hypothalamic obesity conversion, pipeline probability, and operating leverage rather than current earnings. The margin of safety is limited unless the reader gives high probability to sustained revenue growth and eventual profitability. Buffett-style question: if the market closed for five years, would the current price be justified by the cash flows the business can reasonably produce?
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RYTM closing price and session range | $108.40 close on July 10, 2026; high $114.95; low $108.22; volume 506,150 | Rhythm Pharmaceuticals official stock information, LSEG data | July 12, 2026 |
| Market cap and shares | $7.43B calculated from $108.40 x 68.532607M shares; 68.532607M shares outstanding as of May 1, 2026 | SEC Q1 2026 Form 10-Q and financial_rigor.py market-cap check | July 12, 2026 |
| FY2025 financial results | $189.76M total revenue; $196.54M net loss; $116.63M negative free cash flow | SEC FY2025 Form 10-K and StockAnalysis financials and cash flow | July 12, 2026 |
| Five-year operating trend | Revenue rose from $3.15M in 2021 to $189.76M in 2025; net income remained negative in each year shown | StockAnalysis standardized income statement | July 12, 2026 |
| Q1 2026 operating results | $60.11M product revenue; $55.64M net loss; $44.19M cash used in operating activities | SEC Q1 2026 Form 10-Q and Rhythm Q1 2026 business update | July 12, 2026 |
| Cash and obligations | $340.6M cash, cash equivalents, and short-term investments; $204.7M total liabilities at March 31, 2026 | SEC Q1 2026 Form 10-Q and Rhythm Q1 2026 release | July 12, 2026 |
| Commercial and regulatory catalysts | IMCIVREE FDA approval for acquired hypothalamic obesity on March 19, 2026; European Commission authorization on May 1; Japan PMDA decision expected in the second half of 2026 | Rhythm Q1 2026 business update and regulatory releases | July 12, 2026 |
| Pipeline evidence | Phase 2 PWS data in 17 treated patients showed a mean BMI reduction of 3.06% at Month 6; the trial remains ongoing | Rhythm ENDO 2026 data release | July 12, 2026 |
| Dilution and financing | 2.367647M common shares issued in the July 2025 follow-on offering; February 2026 ATM permits up to $200M of common stock sales | SEC Q1 2026 Form 10-Q | July 12, 2026 |
| Technical snapshot | 50-day average $93.99; 200-day average $98.41; RSI 75.08; beta 1.88; 20-day average volume 1.105M shares | StockAnalysis statistics, checked before the July 10 close | July 12, 2026 |
| Analyst price reference | $139.73 average target from 16 analysts shown by StockAnalysis; not company guidance and not a guaranteed outcome | StockAnalysis statistics and forecast data | July 12, 2026 |
| Valuation calculation record | Negative TTM P/E 34.63x; P/B 60.22x; negative P/FCF 59.89x; three-scenario negative reference values because TTM EPS is negative | Local financial_rigor.py verify-valuation and three-scenario commands | July 12, 2026 |
This RYTM AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, reimbursement, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
